Bio-Thera Gains the CHMP’s Positive Opinion of Avzivi (Biosimilar, Avastin)
Shots:
- The CHMP has granted a positive opinion to the company’s Avzivi (bevacizumab), a biosimilar of Avastin to treat metastatic colorectal cancer
- The opinion was based on a P-I study assessing the PK, safety & immunogenicity of Avzivi vs EU & US reference product among healthy subjects & a P-III confirmatory trial of Avzivi vs Avastin among advanced non-squamous NSCLC patients, Results showed similarity b/w the products
- Under the license agreement of 2021, Bio-Thera will develop and manufacture Avzivi, while Sandoz has commercial rights in US, EU, Canada & selected regions
Ref: Bio-Thera Solutions | Image: Bio-Thera Solutions
Related News:- Bio-Thera Reports the US FDA’s Approval of Avzivi (Biosimilar, Avastin)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
